Legal & General Group
PRLD icon

Legal & General Group’s Prelude Therapeutics PRLD Stock Holding History

Legal & General Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Buy
+2,699
New +$11.7K ﹤0.01% 3237
2025
Q2 		– Sell
-962
Closed -$739 – 3508
2025
Q1 		$739 Hold
962
– – ﹤0.01% 3373
2024
Q4 		$1.23K Hold
962
– – ﹤0.01% 3386
2024
Q3 		$1.99K Hold
962
– – ﹤0.01% 3399
2024
Q2 		$3.67K Hold
962
– – ﹤0.01% 3394
2024
Q1 		$4.56K Hold
962
– – ﹤0.01% 3307
2023
Q4 		$4.11K Hold
962
– – ﹤0.01% 3339
2023
Q3 		$2.97K Hold
962
– – ﹤0.01% 3390
2023
Q2 		$4.33K Buy
+962
New +$5.75K ﹤0.01% 3378
2022
Q2 		– Sell
-3,914
Closed -$27K – 3625
2022
Q1 		$27K Hold
3,914
– – ﹤0.01% 3156
2021
Q4 		$49K Buy
3,914
+956
+32% +$15.6K ﹤0.01% 3037
2021
Q3 		$92K Buy
2,958
+1,841
+165% +$59.6K ﹤0.01% 2872
2021
Q2 		$32K Buy
1,117
+69
+7% +$2.46K ﹤0.01% 3114
2021
Q1 		$45K Buy
1,048
+44
+4% +$2.92K ﹤0.01% 2845
2020
Q4 		$72K Sell
1,004
-60,485
-98% -$3.01M ﹤0.01% 2684
2020
Q3 		$1.85M Buy
+61,489
New +$1.74M ﹤0.01% 1791

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Legal & General Group's PRLD Position: Q2 2026 in Review

Legal & General Group opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 2,699 shares worth $14.4K. The stake represents ﹤0.01% of the portfolio and ranks #3237 among its holdings. This is a return to the name: Legal & General Group previously reported a position in PRLD as recently as Q1 2025.

Legal & General Group first reported a position in PRLD in Q3 2020 and has held it in 16 quarters since. The position peaked at $1.85M in Q3 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Legal & General Group held 2,699 shares of Prelude Therapeutics worth $14.4K as of Q2 2026.
  • Prelude Therapeutics was a new Legal & General Group position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3237 holding.
  • Legal & General Group first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 16 quarters since.
  • Legal & General Group's Prelude Therapeutics position peaked at $1.85M in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.